Clinical Trial Update: Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx® [Phase 1]

View source ↗

Summary

Phase 1 dose study in healthy males evaluating safety, pharmacokinetics and pharmacodynamics of NNC126-0083 compared with Norditropin SimpleXx.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• NNC126-0083
• Norditropin SimpleXx (somatropin)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Healthy | Phase 1 | Status: COMPLETED